[Heparin-induced thrombocytopenia: Update].

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Heparin-induced thrombocytopenia (HIT) is a significant adverse effect of heparin anticoagulation.
• HIT involves antibodies against heparin-platelet factor 4 (PF4) complexes, leading to platelet activation and thrombosis.
• Clinical manifestations include a drop in platelet count and increased risk of venous or arterial thrombosis.

Purpose of the Study:

• To outline the diagnostic criteria and management strategies for heparin-induced thrombocytopenia.
• To emphasize the importance of early recognition and intervention in HIT cases.
• To highlight the complexity and multidisciplinary approach required for HIT management.

Main Methods:

• Diagnosis relies on clinical assessment (e.g., 4Ts score) and laboratory confirmation of heparin-PF4 antibodies.
• Immunological assays are followed by functional tests if positive.
• Management involves immediate cessation of heparin, lower limb Doppler ultrasound, and alternative anticoagulation.

Main Results:

• Positive immunological tests for heparin-PF4 antibodies confirm HIT.
• Alternative anticoagulants like danaparoid sodium and argatroban are currently authorized.
• Timely intervention significantly reduces thrombotic risk.

Conclusions:

• Heparin-induced thrombocytopenia diagnosis requires integrated clinical and laboratory assessment.
• Urgent cessation of heparin and initiation of alternative anticoagulation are critical.
• Effective HIT management necessitates a collaborative, multidisciplinary approach.